We value the expertise and commitment of healthcare providers and support them in finding new ways to help patients.
We are applying our scientific leadership in the kallikrein-kinin system and oral drug discovery to develop oral protease inhibitor medicines for patients with diseases caused by the proteases plasma kallikrein and Factor XIIa.
KalVista is focused on developing new oral treatments for HAE.
We’re not just developing drugs for HAE; we also care about the patient journey. We invite healthcare professionals to visit Mind The HAE Attack to learn more about the perspectives and experiences of patients and their views about on-demand treatment to manage HAE.
If you have questions, our medical information team would be happy to speak with you. Please contact us either by phone or email at: